Lorvotuzumab mertansine
Lorvotuzumab mertansine is an antibody-drug conjugate. It comprises the CD56-binding antibody, lorvotuzumab, with a maytansinoid cell-killing agent, DM1, attached using a disulfide linker, SPP.
Lorvotuzumab mertansine is an experimental agent created for the treatment of CD56 positive cancers.
It has been granted Orphan drug status for Merkel cell carcinoma.
It has reported encouraging Phase II results for small-cell lung cancer.
